Lupin ties with global agencies to increase patient access to tuberculosis prevention treatment

7 Oct 2022 , 03:05 PM

Global pharma major, Lupin Limited has announced that it has reached an agreement with Unitaid, The Aurum Institute, the Clinton Health Access Initiative (CHAI), and other global procurement agencies to support tuberculosis prevention treatment that will be rolled out to 138 countries, including many low-and middle-income countries with a large burden of TB.

As per the official statement, through this agreement, Lupin will introduce two new formulations, a fixed-dose combination of Rifapentine + Isoniazid and Rifapentine 300 mg standalone tablets, at an affordable price.

As a global leader in anti-TB medicines, Lupin is committed to ensuring its products are widely available in all countries and there is equitable access to treatment globally.

“We are committed to enhancing the global access to affordable and high-quality drugs and APIs for the treatment of tuberculosis. We are glad to partner on these important products as this closely aligns with our mission of building better health, globally. Through this, we will further reinforce our long legacy to provide shorter, more patient-friendly treatment options to prevent TB,” said Nilesh Gupta, Managing Director, Lupin.

“Lupin continues its accelerated efforts in line with WHO’s The End TB Strategy program. Our expertise in fermentation-based products and backward integration for Rifapentine, enables us to be in a unique position to provide affordable, quality TB prevention and treatment options, and save lives globally,” said Naresh Gupta, President — API and Global Institution Business, Lupin.

At around 3:05 PM, Lupin Ltd is currently trading at Rs722.10 per share down by Rs0.95 or 0.13% from its previous closing of Rs723.05 per share on the BSE.

For feedback and suggestions, write to us at [e-mail]